US Patent 11753644 Compounds and methods for reducing IFNAR1 expression
Patent 11753644 was granted and assigned to Ionis Pharmaceuticals, Inc. on September, 2023 by the United States Patent and Trademark Office.
All edits
US Patent 11753644 Compounds and methods for reducing IFNAR1 expression
Provided are oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of IFNAR1 RNA in a cell or animal, and in certain instances reducing the amount of IFNAR1 protein in a cell or animal Such oligomeric compounds, methods, and pharmaceutical compositions are useful to treat diseases and conditions associated with neuroinflammation, including Aicardi-Goutières Syndrome, stroke, neuropsychiatric systemic lupus erythematosus, neuroinflammation following traumatic brain injury, neuro-autoimmune disorders, Alzheimer's disease, post-operative delirium and cognitive decline, cranial radiation-induced cognitive decline, viral infection-induced cognitive decline, neuromyelitis optica, and ataxia telangiectasia.
Find more entities like US Patent 11753644 Compounds and methods for reducing IFNAR1 expression
